Pre-Conference Discussions Day

Tuesday April 27, 2021

Workshop A: Analyzing the Impact of COVID-19 on Interstitial Lung Disease Treatment for 2021 & Beyond
9.00 - 11.00 EDT | 6.00 - 8.00 PDT

It is no secret that some survivors of COVID-19 suffer with long term fibrotic disease and many questions about the evolution and progression of fibrosis in these patients remain unanswered.

What is the latest consensus on the epidemiology of COVID-19 induced fibrosis? Is the mechanism of fibrosis in coronavirus patients distinct? How should you adapt your approach to treat patients who suffer with ‘long COVID? Join this workshop to have all your burning coronavirus related ILD questions answered and more.

Highlights include:

  • Reviewing the latest research on the epidemiology and mechanisms of COVID-19 induced fibrosis to determine how to accurately predict the development of the fibrosing ILD phenotype in COVID patients
  • Comparing and contrasting the mechanism of fibrosis in COVID-19 patients to other fibrosing pulmonary diseases to understand the scope for existing medicines to treat COVID-19 induced fibrosis
  • A new frontier for fibrosis prevention? Investigating the potential to take a preventative approach to tackling fibrosis in coronavirus patients and understanding how this could impact treatment strategies for other fibrosing pulmonary phenotypes
Workshop Leaders:
Gisli Jenkins, Uni of Nottingham

Gisli Jenkins,
University of Nottingham

Ling Pei Ho

Ling-Pei Ho
Associate Professor Respiratory Immunology 
University of Oxford 

Emily Fraser
Consultant - Respiratory Medicine

Workshop B: Exploring Tools for Interstitial Lung Disease Diagnosis
11:30-1.30 EDT | 8.30-10.30 PDT

Confidently diagnosing the correct type of ILD and developing a tailored treatment plan which results in relieved symptoms and increases quality of life is an issue which has challenged clinicians and researchers alike for decades.

Make sure you are at the forefront of the conversation on the latest developments in the use of new tools and techniques for the accurate diagnosis of ILDs by joining this expert-led session:

Highlights include:

  • Outlining how to develop a comprehensive diagnosis strategy which considers key disease indicators and results in earlier diagnosis
  • Assessing the benefits and drawbacks of standardizing diagnosis across ILDs and understanding how to determine whether this approach is suitable for your patients
  • Exploring innovative tools to diagnose ILDs: learning about the experiences and future perspectives with novel diagnostic techniques
Workshop Leaders:
Marlies Wijsenbeek

Marlies Wijsenbeek,
Pulmonary Physician,
Erasmus University

Karen Moor

Karen Moore,
Pulmonologist & Postdoctoral Researcher,

Erasmus University


Maximiliano Tamae Kakazu,
Assistant Professor of Medicine,
Michigan State    

Monica Bengus

Monica Bengus,
Senior Medical Director,


Workshop C: Optimizing Patient Recruitment for Interstitial Lung Disease Clinical Trials
2.00 - 4.00 EDT | 11.00 - 1.00 PDT

Interstitial lung diseases bring an array of unique challenges to the effective
design and execution of a clinical trial. Addressing various factors associated
with patient selection and minimizing barriers for patients to participate in the
clinical trials. This workshop will allow you to implement a more effective clinical
trial to maximize valuable output and achieve therapeutic benefit.

Highlights include:

• Understanding the risk-reward profile of interstitial lung disease clinical
trials from a patient perspective and learning how to tailor your recruitment
strategy to appeal to potential patients
• Hearing how to systematically select patients whose disease progression aligns
with your clinical trial design to streamline the measurement of the efficacy of
your therapeutic
• Discovering tips and tricks to maximize patient engagement and cooperation
over pro-longed clinical trials
• Optimizing patient experience considering the nature of the treatment

Workshop Leaders:
Mark Hamblin

Mark Hamblin
Assistant Professor - Pulmonary & Critical Care Medicine 
University of Kansas Hospital

Steve Jones

Steve Jones